Cre8 Drug Eluting Stent Performance in Daily Cardiology Practice

Area of Science:

• Cardiology
• Interventional Cardiology
• Biomaterials Science

Background:

• Drug-eluting stents (DES) are standard for percutaneous coronary intervention (PCI).
• Key DES performance factors include stent design, alloy, polymer coating biocompatibility, and drug properties.
• Cre8 is a polymer-free amphilimus-eluting stent (PF-AES).

Purpose of the Study:

• To evaluate the clinical efficacy and safety of Cre8 PF-AES in routine cardiology practice.
• To compare Cre8 stent performance against existing drug-eluting stents.

Main Methods:

• Retrospective analysis of patients treated with Cre8 DES between December 2015 and 2016.
• Inclusion criteria: chronic or acute coronary syndrome patients undergoing PCI with Cre8 DES.
• Data collected on patient demographics, lesion characteristics, procedural success, and clinical outcomes.

Main Results:

• 808 lesions in 664 patients were analyzed; mean follow-up was 487 days.
• Procedural success rate was 97.3%.
• Target lesion failure (TLF) occurred in 6.4% of lesions; cardiac death in 3.0%; target vessel revascularization (TVR) in 4.4%.

Conclusions:

• Cre8 stents show clinical efficacy and safety in real-world settings.
• Outcomes are comparable to latest-generation DES in randomized trials.
• Diabetes and ejection fraction were identified as predictors of mortality and TLF.